EPM
AIMT

Equitec Proprietary Markets’s Aimmune Therapeutics AIMT Stock Holding History

Equitec Proprietary Markets’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-103,800
Closed -$3.58M – 151
2020
Q3 		$3.58M Buy
+103,800
New +$2.21M 2.73% 10

Equitec Proprietary Markets's AIMT Position: Q4 2020 in Review

Equitec Proprietary Markets sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 103,800 shares — an estimated $3.58M sold.

Equitec Proprietary Markets first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $3.58M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Equitec Proprietary Markets reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Equitec Proprietary Markets sold 103,800 Aimmune Therapeutics shares in Q4 2020, an estimated $3.58M.
  • Equitec Proprietary Markets first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Equitec Proprietary Markets's Aimmune Therapeutics position peaked at $3.58M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Equitec Proprietary Markets's 13F filing for Q4 2020, filed 26 Jan 2021.